| The human cytomegalovirus terminase complex as an antiviral target: a close-up view G Ligat, R Cazal, S Hantz, S Alain FEMS microbiology reviews 42 (2), 137-145, 2018 | 106 | 2018 |
| Hepatitis C virus (HCV)–apolipoprotein interactions and immune evasion and their impact on HCV vaccine design F Wrensch, E Crouchet, G Ligat, MB Zeisel, ZY Keck, SKH Foung, ... Frontiers in immunology 9, 1436, 2018 | 48 | 2018 |
| Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives V Taverniti, G Ligat, Y Debing, DB Kum, TF Baumert, ER Verrier Journal of clinical medicine 11 (5), 1349, 2022 | 38 | 2022 |
| Hepatitis B virus core variants, liver fibrosis, and hepatocellular carcinoma G Ligat, C Schuster, TF Baumert Hepatology 69 (1), 5-8, 2019 | 26 | 2019 |
| Hepatitis B virus–host interactions and novel targets for viral cure G Ligat, ER Verrier, M Nassal, TF Baumert Current opinion in virology 49, 41-51, 2021 | 25 | 2021 |
| Interferon‐Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection F Wrensch, G Ligat, L Heydmann, C Schuster, MB Zeisel, P Pessaux, ... Hepatology 70 (5), 1506-1520, 2019 | 24 | 2019 |
| Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: benefits and limits of 3D analysis D Andouard, MC Mazeron, G Ligat, A Couvreux, C Pouteil-Noble, ... Antiviral Research 129, 115-119, 2016 | 23 | 2016 |
| Targeting viral cccDNA for cure of chronic hepatitis B G Ligat, K Goto, E Verrier, TF Baumert Current hepatology reports 19, 235-244, 2020 | 19 | 2020 |
| Identification of amino acids essential for viral replication in the HCMV helicase-primase complex G Ligat, S Da Re, S Alain, S Hantz Frontiers in Microbiology 9, 412785, 2018 | 18 | 2018 |
| Structures and divergent mechanisms in capsid maturation and stabilization following genome packaging of human cytomegalovirus and herpesviruses C Muller, S Alain, TF Baumert, G Ligat, S Hantz Life 11 (2), 150, 2021 | 17 | 2021 |
| Identification of a short sequence in the HCMV terminase pUL56 essential for interaction with pUL89 subunit G Ligat, C Jacquet, S Chou, A Couvreux, S Alain, S Hantz Scientific Reports 7 (1), 8796, 2017 | 15 | 2017 |
| Highlighting of a LAGLIDADG and a zing finger motifs located in the pUL56 sequence crucial for HCMV replication G Ligat, A Couvreux, R Cazal, S Alain, S Hantz Viruses 11 (12), 1093, 2019 | 6 | 2019 |
| The terminase complex, a relevant target for the treatment of HCMV infection G Ligat, C Muller, S Alain, S Hantz Medecine Sciences: M/S 36 (4), 367-375, 2020 | 5* | 2020 |
| Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target ER Verrier, G Ligat, L Heydmann, K Doernbrack, J Miller, A Maglott-Roth, ... Gut 72 (9), 1745-1757, 2023 | 4 | 2023 |
| New insights into human cytomegalovirus pUL52 structure C Muller, S Alain, C Gourin, TF Baumert, G Ligat, S Hantz Viruses 13 (8), 1638, 2021 | 4 | 2021 |
| The Yin and the Yang of extracellular vesicles during viral infections C Martin, G Ligat, CE Malnou Biomedical Journal, 100659, 2023 | 3 | 2023 |
| Towards a Prophylactic Vaccine for the Prevention of HCMV Infection G Ligat, S Alain, S Hantz Vaccines 9 (9), 968, 2021 | 1 | 2021 |
| OPEN ACCESS EDITED AND REVIEWED BY A Kramvis, G Ligat, CE Malnou Recent highlights in the development of therapeutic antiviral strategies, 4, 2023 | | 2023 |
| Recent highlights in the development of therapeutic antiviral strategies CE Malnou, G Ligat Frontiers in Microbiology 14, 1338999, 2023 | | 2023 |
| Bringing clinical and fundamental young microbiologists together G Ligat, T Ghelfenstein-Ferreira, S Dellière, M Pichon FEMS microbes 3, xtac025, 2022 | | 2022 |
Thomas BaumertInsermVerified email at unistra.fr
